The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barré Syndrome (GBS), Myasthenia Gravis (MG), Idiopathic Thrombocytopenic Purpura (ITP), and Chronic Lymphocytic Leukemia (CLL). The report also profiles the marketed products, key pipeline products, and leading companies that could change the market landscape in the forecast period. The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Research’s team of industry experts. Research expects the immunoglobulin market to see a slight increase in its growth rate during the 2012–2019 forecast period. It was worth $3.6 billion in 2012, having grown at a Compound Annual Growth Rate (CAGR) of 6% from 2006.

1. Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP) potentially supplemented by approvals for Alzheimers disease
GBI Research’s report: Immunoglobulin Market to 2019 provides in-depth analysis of the global
immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five
European countries (the UK, Germany, France, Italy and Spain) and Japan. The revenue and annual cost of
therapy are forecast for the key geographies and in seven key therapeutic segments, along with epidemiology
data, until 2019.
The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barré Syndrome
(GBS), Myasthenia Gravis (MG), Idiopathic Thrombocytopenic Purpura (ITP), and Chronic Lymphocytic
Leukemia (CLL). The report also profiles the marketed products, key pipeline products, and leading
companies that could change the market landscape in the forecast period.
The report has been built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GBI Research’s team of industry experts. GBI Research
expects the immunoglobulin market to see a slight increase in its growth rate during the 2012–2019
forecast period. It was worth $3.6 billion in 2012, having grown at a Compound Annual Growth Rate (CAGR)
of 6% from 2006. Demand for immunoglobulin products continues to increase due to growing disease
awareness and therapeutic usage in a wide range of therapeutic areas. Immunology and neurology are the
disciplines that use the most immunoglobulins, while PI and CIDP are the top indications.
Geographically, the US is the largest market, commanding a share of over 70% of the global market. 11 new
products have been approved in the US since 2006, but as many are for PI or ITP, immunoglobulin usage in
the US remains off-label for all other indications. Baxter, CSL Behring, and Grifols continue to command the
top ranks in terms of revenue, and recent approvals of Subcutaneous Immunoglobulins (SCIGs) in the US and
Europe will further boost market growth.
Scope
Annualized market data for the immunoglobulin market from 2006 to 2012 and forecast to 2019 Analysis of
the seven key therapeutic segments: PI, CIDP, MMN, MG, CLL, GBS and ITP Analysis of the
immunoglobulins markets in the leading global geographies: the US, the top five European countries, and
Japan Market characterization of the immunoglobulin market, covering size, revenue analysis by geography,
annual cost of therapy, and epidemiology Key drivers and barriers that have a significant impact on the market
Coverage of key marketed products, approved indications, and safety and efficacy profiles Coverage of the
pipeline molecules in various phases of drug development Competitive profiling of the leading companies:
Baxter, Biotest, Bio Products Laboratory, CSL Behring, Grifols, and Octapharma Key M&A activity and
licensing agreements between 2012 and mid-2013 in the global immunoglobulin market Overview of the
immunoglobulin markets in Asia-Pacific and China, covering regulations, key players and marketed products
Reasons to Buy
Align your product portfolio to the markets with high growth potential Develop market-entry and
market-expansion strategies by identifying the leading therapeutic segments and geographic markets poised
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C

2. for strong growth Develop key strategic initiatives by understanding the key focus areas of the leading
companies Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio
gaps
table Of Content
1 Table Of Contents
1.1 List Of Tables
1.2 List Of Figures
2 Immunoglobulins Market To 2019 - Introduction
2.1 Overview
3 Immunoglobulins Market To 2019 - Market Overview
3.1 Revenue
3.2 Annual Cost Of Therapy
3.3 Immunoglobulins Market Drivers And Restraints
3.3.1 Market Drivers
3.3.2 Restraints
4 Immunoglobulins Market To 2019 - Geographical Landscape
4.1 Us
4.1.1 Revenue
4.1.2 Annual Cost Of Therapy
4.2 Top Five European Countries
4.2.1 Revenue
4.2.2 Annual Cost Of Therapy
4.3 Japan
4.3.1 Revenue
4.3.2 Annual Cost Of Therapy
5 Immunoglobulins Market To 2019 - Therapeutic Landscape
5.1 Main Therapeutic Indications
5.1.1 Indicated Conditions For Intravenous Immunoglobulin Usage - Us
5.1.2 Indications For Intravenous Immunoglobulin Usage - Europe
5.1.3 Guidelines For Intravenous Immunoglobulin Usage - Uk
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C

3. 5.1.4 Indications For Intravenous Immunoglobulin Usage - Japan
5.2 Revenue Share For The Major Therapeutic Indications
5.3 Primary Immunodeficiency Market
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Annual Cost Of Therapy
5.3.4 Epidemiology
5.3.5 Current Use
5.3.6 Geographical Segmentation
5.4 Guillain-barré Syndrome Market
5.4.1 Introduction
5.4.2 Revenue
5.4.3 Annual Cost Of Therapy
5.4.4 Epidemiology
5.4.5 Current Use For Therapies
5.4.6 Geographical Segmentation
5.5 Chronic Lymphocytic Leukemia Market
5.5.1 Introduction
5.5.2 Revenue
5.5.3 Annual Cost Of Therapy
5.5.4 Epidemiology
5.5.5 Current Use
5.5.6 Geographical Segmentation
5.6 Chronic Inflammatory Demyelinating Polyneuropathy Market
5.6.1 Introduction
5.6.2 Revenue
5.6.3 Annual Cost Of Therapy
5.6.4 Epidemiology
5.6.5 Current Use
5.6.6 Geographical Segmentation
5.7 Myasthenia Gravis Market
5.7.1 Introduction
5.7.2 Revenue
5.7.3 Annual Cost Of Therapy
5.7.4 Epidemiology
5.7.5 Current Use
5.7.6 Geographical Segmentation
5.8 Multifocal Motor Neuropathy Market
5.8.1 Introduction
5.8.2 Revenue
5.8.3 Annual Cost Of Therapy
5.8.4 Epidemiology
5.8.5 Current Use
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C

4. 5.8.6 Geographical Segmentation
5.9 Idiopathic Thrombocytopenic Purpura
5.9.1 Introduction
5.9.2 Revenue
5.9.3 Annual Cost Of Therapy
5.9.4 Epidemiology
5.9.5 Current Use
5.9.6 Geographical Segmentation
6 Immunoglobulins Market To 2019 - Profiles Of Marketed Products
6.1 Overview
6.2 Privigen
6.2.1 Overview
6.2.2 Approved Indications
6.2.3 Safety
6.2.4 Efficacy
6.3 Gammagard S/d
6.3.1 Overview
6.3.2 Approved Indications
6.3.3 Safety
6.3.4 Efficacy
6.4 Gammagard Liquid
6.4.1 Overview
6.4.2 Approved Indications
6.4.3 Safety
6.4.4 Efficacy
6.5 Octagam 5%
6.5.1 Overview
6.5.2 Approved Indications
6.5.3 Safety
6.5.4 Efficacy
6.6 Flebogamma 10% Dif
6.6.1 Overview
6.6.2 Approved Indications
6.6.3 Safety
6.6.4 Efficacy
6.7 Gamunex-c
6.7.1 Overview
6.7.2 Approved Indications
6.7.3 Safety
6.7.4 Efficacy
6.8 Gammaplex
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C

5. 6.8.1 Overview
6.8.2 Approved Indications
6.8.3 Safety
6.8.4 Efficacy
6.9 Hyqvia
6.9.1 Overview
6.9.2 Approved Indications
6.9.3 Safety
6.9.4 Efficacy
6.10 Bivigam
6.10.1 Overview
6.10.2 Approved Indications
6.10.3 Safety
6.10.4 Efficacy
7 Immunoglobulins Market To 2019 - Pipeline Analysis
7.1 Research And Development Pipeline
7.2 Major Pipeline Product Profiles
7.2.1 Ivig3i Grifols 10%
7.2.2 Ri-002 (ivig)
8 Immunoglobulins Market To 2019 - Competitive Landscape
8.1 Baxter International Inc.
8.1.1 Business Description
8.1.2 Recent Developments
8.2 Biotest Pharmaceuticals
8.2.1 Business Description
8.2.2 Recent Developments
8.3 Bio Products Laboratory Ltd.
8.3.1 Business Description
8.3.2 Recent Developments
8.4 Csl Behring Limited
8.4.1 Business Description
8.4.2 Recent Developments
8.5 Grifols S.a.
8.5.1 Business Description
8.5.2 Recent Developments
8.6 Octapharma Ag
8.6.1 Business Description
8.6.2 Recent Developments
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C

6. 9 Immunoglobulins Market To 2019 - M&a And Licensing Deals Landscape
9.1 M&a Deals
9.1.1 Grifols Buys 60% Of Progenika Biopharma
9.1.2 Grifols Acquires 40% Of The Capital Of Biotechnology Firm Vcn Bioscience
9.1.3 Grifols Purchases Three Plasma Donation Centers In The Us From Canada’s Cangene
9.1.4 Baxter Enhances Renal Therapies Portfolio With Acquisition Of Gambro
9.2 R&d Licensing Agreements
9.2.1 Baxter And Onconova Announce European Licensing Agreement For Anti-cancer Compound
Rigosertib
9.2.2 Baxter Announces Collaboration With Sanquin To Expand Capacity For Plasma Therapies
9.2.3 Baxter Announces 20 Year Partnership With Hemobras In Brazil
10 Immunoglobulins Market To 2019 - Asia-pacific And China
10.1 India
10.1.1 Overview
10.1.2 Regulatory Landscape
10.1.3 National Institute For Biologicals
10.1.4 Marketed Products
10.1.5 Product Profiles
10.1.6 Company Profiling
10.2 China
10.2.1 Overview
10.2.2 Regulatory Information
10.2.3 Marketed Products
10.2.4 Company Profiling
10.3 Australia
10.3.1 Overview
10.3.2 Regulatory Landscape
10.3.3 Marketed Products
10.3.4 Product Profiles
10.3.5 Company Profiling
11 Global Immunoglobulins Market: Appendix
11.1 Market Definitions
11.2 Abbreviations
11.3 References
11.4 Research Methodology
11.4.1 Coverage
11.4.2 Secondary Research
11.4.3 Primary Research
11.4.4 Expert Panel Validation
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C

7. 11.5 Contact Us
11.6 Disclaimer
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C